3 edition of Regional antineoplastic drug delivery in the management of malignant disease found in the catalog.
Regional antineoplastic drug delivery in the management of malignant disease
Includes bibliographical references (p. 93-138) and index.
|Series||The John Hopkins series in contemporary medicine and public health|
|LC Classifications||RC271.C5 M27 1991|
|The Physical Object|
|Pagination||xii, 143 p. ;|
|Number of Pages||143|
|LC Control Number||90015596|
Nanocarriers for drug delivery. Nanomedicine is a rapidly developing area that is revolutionizing cancer diagnosis and therapy. Nanoparticles . The delivery of antineoplastic therapy via the intravenous route is a long-standing, critical, and well-coordinated component of oncology practice. But .
advantage following intraperitoneal drug delivery (Table 1); . Intraperitoneal cisplatin The greatest experience with intraperitoneal chemo-therapy has been with cisplatin, based on its central role in the management of ovarian cancer. Several Table 2 Unique issues associated with intraperitoneal antineoplastic drug delivery 1. Intraperitoneal chemotherapy in the management of malignant disease. AU Markman M SO Expert Rev Anticancer Ther. Jun;1(1) The intraperitoneal administration of antineoplastic agents has been proposed as a method to improve the efficacy of therapy of malignant disease principally confined to the peritoneal cavity.
About Neoplastic Diseases: Neoplastic Diseases are conditions containing a neoplasm, an abnormal tissue that grows by cellular proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth sms usually form a distinct mass of tissue that may be either benign (benign tumor) or malignant (cancer). Bacterial ghosts from gram-negative bacteria obtained by E-mediated lysis have importance in immunotherapy for DNA-based animal vaccines or for the delivery of antineoplastic drugs in cancer cells. Exosomes are extracellular vesicles from endocytic compartments of different types of eukaryotic cells that have applications as delivery systems of.
Single Shot (Johnny Ace)
Networking as a method of rural human service delivery
Undine [by] Friedrich de la Motte Fouqué.
Business at Boom Farm, and
eGrade Plus Stand-alone for Finite Mathematics
Local index of the Dumfries and Galloway standard and advertiser and its predecessors over 200 years.
Photocycloadditions of 1, 3-dienes to anthracenes
Coleridge and German idealism
Inroads of the outback
In Regional Chemotherapy: Clinical Research and Practice, Maurie Markman and a panel of distinguished clinicians and leading clinical investigators comprehensively review the current status of regional antineoplastic drug delivery in the management of malignant disease.
Additional Physical Format: Online version: Markman, Maurie. Regional antineoplastic drug delivery in the management of malignant disease. Baltimore: Johns Hopkins University Press, © The regional delivery of anticancer agents is not a new concept. Following the recognition that cytotoxic alkylating drugs could cause shrinkage of tumors and a reduction in the quantity of malignant ascites in individuals with advanced ovarian cancer, researchers in the s instilled the agents directly into the peritoneal cavity in an effort to treat the malignancy.1 The intrathecal Author: Maurie Markman.
Despite the attraction of regional anticancer drug delivery in the treatment of malignant conditions principally confined to a particular body region, a number of important theoretical objections can be raised regarding the clinical relevance of this therapeutic : Maurie Markman. survival advantage with regional drug delivery.
Although a rationale can be proposed for intraperitoneal antineoplastic drug delivery in non-ovarian malignant disease involving the peritoneal cavity, current data do not support the use of this strategy outside the confines of well-designed clinical trials.
Lancet Oncol ; 4: – The cytotoxic potential of current chemotherapeutic agents is far less in this group of malignant diseases than in ovarian cancer.
Surgical cytoreduction is a rare treatment in these malignant states but such surgery is common in the treatment of ovarian cancer and aids the optimum use of regional antineoplastic drug delivery. Abstract. Regional antineoplastic drug delivery is not a new concept. Following the initial recognition that cytotoxic alkylating agents could cause shrinkage of tumor masses and a reduction in the quantity of malignant ascites in patients with advanced ovarian cancer, investigators in the s instilled the drugs directly into the peritoneal cavity in an effort to treat the malignancy (1).
The use of intraperitoneal drug delivery in the treatment of malignant disease confined to the peritoneal cavity is based on the theoretical potential for increased exposure of the tumour to antineoplastic agents leading to improved cytotoxicity.
Phase I studies have explored the safety and pharmacokinetic advantage of the regional administration of several drugs, including cisplatin (10. The intraperitoneal administration of antineoplastic agents has been proposed as a method to improve the efficacy of therapy of malignant disease principally confined to the peritoneal cavity.
Phase I studies have demonstrated the safety and pharmacokinetic advantage for a number of drugs delivered directly into the body compartment, with. The basic aim of intraperitoneal chemotherapy is to expose tumor present within the cavity to higher concentrations of drug for longer periods of time than can be achieved with systemic delivery of the agent.[2, 3, 6] The specific characteristics of an antineoplastic agent that would make it attractive to consider for regional delivery are outlined in Table Antineoplastic drugs, also known as chemotherapy, cytotoxic and oncology drugs, are used to treat cancer, as well as arthritis, multiple sclerosis, and other non-cancer medical conditions.
Most antineoplastic drugs are classified by NIOSH as hazardous drugs. 1 About 8 million U.S. healthcare workers are potentially exposed to hazardous drugs. Intraperitoneal chemotherapy in the management of malignant disease Article Literature Review in Expert Review of Anticancer Therapy 1(1) July with 22 Reads How we measure 'reads'.
Regional cancer therapies remain important options in the management of malignant disease, in spite of the venue of more targeted agents for systemic therapies. New te- nologies and better guidance systems for radiofrequency ablation and intrastitial laser therapies, highly selective intravascular.
Antineoplastic agents frequently disrupt replication at the cellular level by obstructing the synthesis of new genetic material or by causing irreversible damage to the DNA itself. While this affects both normal and malignant cells, normal cells have a greater ability to repair minor damage and continue living.
Maurie Markman, Intraperitoneal antineoplastic drug delivery: rationale and results, The Lancet Oncology, /S(03)X, 4, 5, (), (). Crossref.
This paper gives an overview of different toxicities of anticancer drugs and its management. [Int J Basic Clin Pharmacol ; 1(): ] Discover the world's research. Antineoplastic drugs are also called anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
These drugs come in many forms. Some are liquids that are injected into the patient and some are pills that patients take.
Abstract. Both pre-clinical studies and phase 1–2 clinical trials have provided strong support for the potential role of regional drug delivery in the management of epithelial ovarian cancer, a disease process whose major manifestations remain largely localized to the peritoneal cavity in the majority of individuals with this malignancy.
Milton and M. Lane Brown, THE LIMITED ROLE OF ATTENUATED SMALLPOX VIRUS IN THE MANAGEMENT OF ADVANCED MALIGNANT MELANOMA*, Australian and New Zealand Journal of Surgery, 35, 4, (), ().
Title: Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma VOLUME: 6 ISSUE: 3 Author(s):Georg Karpel-Massler, Christian R. Wirtz and Marc-Eric Halatsch Affiliation:Department of Neurosurgery, University of Ulm School of Medicine, Steinhovelstr.
9, D Ulm, Germany. Keywords:Erlotinib, high-grade glioma, Kit, pralatrexate, romidepsin, vascular. management of small-volume residual advanced ovarian cancer. This study is particularly relevant because it utilizes the intraperitoneal route to administer both the most active drug in ovarian cancer (a platinum agent) and the drug with the most profound pharmacokinetic advantage for cavity exposure (paclitaxel) following regional delivery.
Anticancer Drug, also called Anti-Neoplastic drug, that is effective in the treatment of malignant, or cancerous, disease.
There are several major classes of anticancer drugs; these include Alkylating Agents, Anti-metabolites, Plant Alkaloids and Hormones.Find comprehensive medical reference information including disease symptoms, diagnoses, treatments, and follow-up; plus drug and medication dosing, interactions, adverse effects, and more on Medscape, a free, comprehensive, and current resource for physicians and other healthcare professionals.